Konferanseforedrag

• Eidi Christensen; Erik Mørk; Olav A. Foss et al. (2025). Simplified procedure for PDT in BCC. (ekstern lenke)
• Erik Mørk; Patricia Mjønes; Olav A. Foss et al. (2022). Clinical versus punch biopsy assessment of BCC subtype and thickness within a PDT-setting. (ekstern lenke)

Konferanseabstrakt

• Ingeborg M. Bachmann; HE Eknes; Ariel P. Otte et al. (2007). Loss of BMI-1 expression is associated with the clinical progress of malignant melanoma. (ekstern lenke)
• Erik Mørk; Patricia Mjønes; Olav A. Foss et al. (2022). How well do experienced dermatologists clinically assess basal cell carcinoma subtype and thickness before treatment with photodynamic therapy?. (ekstern lenke)

Vitenskapelig artikkel

• Rita Grude Ladstein; Ingeborg M. Bachmann; Oddbjørn Straume et al. (2010). Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. (ekstern lenke)
• Hanne Eknes Puntervoll; Xiaohong R. Yang; Hildegunn Høberg Vetti et al. (2013). Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. (ekstern lenke)
• Rita Grude Ladstein; Ingeborg M. Bachmann; Oddbjørn Straume et al. (2012). Tumor necrosis is a prognostic factor in thick cutaneous melanoma. (ekstern lenke)
• Erik Mørk; Patricia Gjertrud Mjønes; Olav A. Foss et al. (2024). Clinical versus Histological Assessment of Basal Cell Carcinoma Subtype and Thickness of Tumours Selected for Photodynamic Therapy. (ekstern lenke)
• Ingeborg Bachmann; Oddbjørn Straume; Lars A. Akslen (2004). Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. (ekstern lenke)
• Lise Mayrin Økland Thunestvedt; Lars Helgeland; Ingeborg Margrethe Bachmann et al. (2022). Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis. (ekstern lenke)
• Lars A. Akslen; Sabrina Angelini; Oddbjørn Straume et al. (2005). BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. (ekstern lenke)
• Emilia Signe Hugdahl; Ingeborg M. Bachmann; Cornelia Schuster et al. (2019). Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma. (ekstern lenke)
• Ingeborg M. Bachmann; Rita Grude Ladstein; Oddbjørn Straume et al. (2008). Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. (ekstern lenke)
• Lars A. Akslen; Hanne Eknes Puntervoll; Ingeborg M. Bachmann et al. (2008). Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. (ekstern lenke)
• Lars F. Iversen; Liv Eidsmo; Joar Austad et al. (2018). Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study. (ekstern lenke)
• Ingeborg Bachmann; Oddbjørn Straume; Hanne Eknes Puntervoll et al. (2005). Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. (ekstern lenke)
• Oddbjørn Straume; Takeshi Shimamura; Michael J.G. Lampa et al. (2012). Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. (ekstern lenke)
• Eidi Christensen; Erik Mørk; Olav Andreas Foss et al. (2024). New, simplified versus standard photodynamic therapy (PDT) regimen for superficial and nodular basal cell carcinoma (BCC): A single-blind, non-inferiority, randomised controlled multicentre study. (ekstern lenke)
• Ingeborg Margrethe Bachmann; Ole Johan Halvorsen; Karin Collett et al. (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. (ekstern lenke)
• Erik Mørk; Patricia Gjertrud Mjønes; Olav A. Foss et al. (2023). Expression of β-Catenin, E-Cadherin, and α-Smooth Muscle Actin in Basal Cell Carcinoma Before Photodynamic Therapy in Non-recurrent and Recurrent Tumors: Exploring the Ability of Predicting Photodynamic Therapy outcome. (ekstern lenke)
• Rita Grude Ladstein; Ingeborg M. Bachmann; Oddbjørn Straume et al. (2014). Nestin expression is associated with aggressive cutaneous melanoma of the nodular type. (ekstern lenke)
• Ingeborg M. Bachmann; Hanne Eknes Puntervoll; Arie P. Otte et al. (2008). Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. (ekstern lenke)
• Rita Grude Ladstein; Ingeborg M. Bachmann; Oddbjørn Straume et al. (2012). Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma. (ekstern lenke)

Konferanseposter

• Erik Mørk; Patricia Mjønes; Olav A. Foss et al. (2022). How well do experienced dermatologists clinically assess basal cell carcinoma subtype and thickness before treatment with photodynamic therapy?. (ekstern lenke)
• Erik Mørk; Patricia Mjønes; Olav A. Foss et al. (2022). Clinical versus histological assessment of basal cell carcinoma for photodynamic therapy. (ekstern lenke)

Doktorgradsavhandling

• Erik Mørk; Eidi Christensen; Patricia Gjertrud Mjønes et al. (2024). Aspects of selection and treatment of basal cell carcinoma for photodynamic therapy. (ekstern lenke)
• Ingeborg M. Bachmann (2007). Biological Markers in Cutaneous Melanoma. A study with special focus on cell cycle regulation, cell adhesion proteins and tumor necrosis. (ekstern lenke)

Leserbrev

• Hanne Sommerfelt; Lene Frøyen Sandvik; Ingeborg Margrethe Bachmann et al. (2022). Toxic epidermal necrolysis after immune checkpoint inhibition, case report, and review of the literature. (ekstern lenke)

Vitenskapelig litteraturgjennomgang

• Jürgen Geisler; Ingeborg M. Bachmann; Marta Sølvi Nyakas et al. (2013). Malignt melanom – diagnostikk, behandling og oppfølging i Norge. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin